Zika alert in India, Hyderabad firm claims to have world’s first vaccine

WHO designates the virus as a public health emergency of international concern

GN Bureau | February 3, 2016


#zika   #virus   #america   #us   #india   #panic  

 The union health ministry has sounded an alert for Zika and appointed the National Centre for Disease Control (NCDC) as the nodal agency for investigation of any outbreak of the viral infection in India.

This comes in the backdrop of the World Health Organization (WHO) designating the virus and its suspected complications in newborns as a public health emergency of international concern.

The virus is transmitted through the bite of an infected Aedes mosquito, which is also known to transmit infections such as dengue and chikungunya. The WHO has named 22 countries as among those affected. The virus causes microcephaly (little head) in the newborn.

Meanwhile, the world’s first vaccine to treat the pandemic has been developed and it’s been developed by India. Bharat Biotech International Limited- a Hyderabad based firm- has made a giant leap ahead of all of them and successfully developed the vaccine already.

BBIL says that it has already patented the vaccine. Speaking to NDTV, the chairman and managing director of the company, Dr Krishna Ella said, “On Zika, we are probably the first vaccine company in the world to file a vaccine candidate patent about nine months ago.” The firm has developed two candidate vaccines, using a live imported Zika virus. However, the trails on animals and humans haven’t begun yet.

Ella says that he has contacted the Indian Council of Medical Research (ICMR) to help with the trials and they have been most cooperative.

Ella said that if all goes well, his firm can churn out 1 million doses of the vaccine in four months. He is all set to seek prime minister Narendra Modi’s direct intervention to expedite the process of fast tracking the vaccine’s development and delivery by skipping regulatory clearances to get the vaccine to the countries that need help including Brazil, where the epidemic first broke.
 

Comments

 

Other News

‘Oral cancer deaths in India cause productivity loss of 0.18% GDP’

A first-of-its-kind study on the economic loss due to premature death from oral cancer in India by the Tata Memorial Centre has found that this form of cancer has a premature mortality rate of 75.6% (34 premature events / 45 total events) resulting in productivity loss of approximately $5.6 billion in 2022

Days of Reading: Upendra Baxi recalls works that shaped his youth

Of Law and Life Upendra Baxi in Conversation with Arvind Narrain, Lawrence Liang, Sitharamam Kakarala, and Sruti Chaganti Orient BlackSwan, Rs 2,310

Voting by tribal communities blossoms as ECI’s efforts bear fruit

The efforts made by the Election Commission of India (ECI), over last two years, for inclusion of Particularly Vulnerable Tribal Groups (PVTG) communities and other tribal groups in the electoral process have borne fruit with scenes of tribal groups in various states/UTs participating enthusiastically in t

GST revenue for April 2024 at a new high

The gross Goods and Services Tax (GST) collections hit a record high in April 2024 at ₹2.10 lakh crore. This represents a significant 12.4% year-on-year growth, driven by a strong increase in domestic transactions (up 13.4%) and imports (up 8.3%). After accounting for refunds, the net GST

First Magahi novel presents a glimpse of Bihar bureaucracy a century ago

Fool Bahadur By Jayanath Pati (Translated by Abhay K.) Penguin Modern Classics, 112 pages, Rs 250 “Bab

Are EVs empowering India`s Green Transition?

Against the backdrop of the $3.5 billion Production-Linked Incentive (PLI) scheme launched by the Government of India, sales of Electric Vehicles (EVs) are expected to grow at a CAGR of 35% by 2032. It is crucial to take into account the fact that 86% of EV sales in India were under the price bracket of $2

Visionary Talk: Amitabh Gupta, Pune Police Commissioner with Kailashnath Adhikari, MD, Governance Now


Archives

Current Issue

Opinion

Facebook Twitter Google Plus Linkedin Subscribe Newsletter

Twitter